Aurora Cannabis reported annual revenue of $246.72 million, representing a 12% increase year-over-year. Despite this top-line growth, the company posted a net income of $1.63 million, translating to an earnings per share loss of $0.69. The firm trades at a price-to-sales ratio of 0.97 and a negative price-to-earnings multiple of –6.13, reflecting market caution around its ability to sustain profitability. Aurora’s net margin stands at –15.96%, while return on equity and return on assets register at –0.58% and –0.42%, respectively, underscoring ongoing pressure on the bottom line as the company continues to scale its operations and invest in new product lines.

Institutional investors hold 47.6% of Aurora’s outstanding shares, signaling significant confidence from large asset managers and hedge funds. Insider ownership remains at 0%, indicating no direct insider purchases in the recent period. Analyst coverage shows a mixed outlook: one sell rating, one hold rating, and one strong-buy recommendation, yielding an average rating score of 2.33 on a 1–5 scale. This divergent sentiment reflects differing views on the company’s path to profitability and its ability to navigate regulatory and industry headwinds.

Aurora operates through three core segments—Canadian cannabis, European cannabis, and plant propagation—supplying medical and adult-use products across multiple international markets. Its branded portfolio includes Aurora Drift, San Rafael ’71 and MedReleaf, targeting both recreational and medical consumers. The company continues to expand its European distribution footprint in Germany and Denmark, while leveraging its plant propagation unit to supply propagated vegetables and ornamental plants in North America. Management has prioritized R&D investments in novel ingestible formats and cannabidiol-derived wellness products, aiming to diversify revenue streams and capture market share as regulatory frameworks evolve.